RESUMEN
The COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to spread around the world. GS-441524 is the parent nucleoside of remdesivir which is the first drug approved for the treatment of COVID-19, and demonstrates strong activity against SARS-Cov-2 in vitro and in vivo. Herein, we reported the synthesis of a series of deuterated GS-441524 analogs, which had deuterium atoms up to five at the ribose and the nucleobase moieties. Compared to GS-441524, all the deuterated compounds showed similar inhibitory activities against SARS-CoV-2 in vitro.
RESUMEN
A series of 2'-deoxy carbocyclic nucleosides characterized by various 6'-substitutions were synthesized and evaluated for their antiviral activities against three viruses, including hepatitis B virus (HBV), hepatitis C virus, and influenza virus. The in vitro antiviral assays indicated that these nucleosides only showed inhibitory activities against HBV, and the substituted groups at the 6' position significantly affected the activity. Among them, the guanosine analog 2b bearing a 6'-α-hydroxyl methyl group was the most potent compound with an EC50 value of 80 nM. The present study provided useful information for the discovery of antiviral carbocyclic nucleosides.
Asunto(s)
Antivirales , Nucleósidos , Antivirales/farmacología , Hepacivirus , Virus de la Hepatitis B , Nucleósidos/farmacologíaRESUMEN
The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2 efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19. However, this nucleoside has a poor oral bioavailability in non-human primates, which may affect its therapeutic efficacy. Herein, we reported a variety of GS-441524 analogs with modifications on the base or the sugar moiety, as well as some prodrug forms, including five isobutyryl esters, two l-valine esters, and one carbamate. Among the new nucleosides, only the 7-fluoro analog 3c had moderate anti-SARS-CoV-2 activity, and its phosphoramidate prodrug 7 exhibited reduced activity in Vero E6 cells. As for the prodrugs, the 3'-isobutyryl ester 5a, the 5'-isobutyryl ester 5c, and the tri-isobutyryl ester 5g hydrobromide showed excellent oral bioavailabilities (F = 71.6%, 86.6% and 98.7%, respectively) in mice, which provided good insight into the pharmacokinetic optimization of GS-441524.
Asunto(s)
Adenosina/análogos & derivados , Antivirales/farmacología , SARS-CoV-2/efectos de los fármacos , Adenosina/farmacocinética , Adenosina/farmacología , Adenosina/toxicidad , Animales , Antivirales/síntesis química , Antivirales/farmacocinética , Antivirales/toxicidad , Chlorocebus aethiops , Masculino , Ratones Endogámicos ICR , Pruebas de Sensibilidad Microbiana , Profármacos/síntesis química , Profármacos/farmacocinética , Profármacos/farmacología , Profármacos/toxicidad , Células VeroRESUMEN
Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV) is widespread in the world. In recent years, the increased virulence of the virus due to viral variations, has caused great economic losses to the pig industry in many countries. It is always worthy to find effective therapeutic methods for PED. As an important class of antivirals, nucleoside drugs which target viral polymerases have been applied in treating human viral infections for half a century. Herein, we evaluated the anti-PEDV potential of three broad-spectrum antiviral nucleoside analogs, remdesivir (RDV), its parent nucleoside (RDV-N) and ß-D-N4-hydroxycytidine (NHC). Among them, RDV-N was the most active agent in Vero E6 cells with EC50 of 0.31 µmol/L, and more potent than RDV (EC50 = 0.74 µmol/L) and NHC (EC50 = 1.17 µmol/L). The activity of RDV-N was further confirmed using an indirect immuno-fluorescence assay. Moreover, RDV-N exhibited a good safety profile in cells and in mice. The high sequence similarity of the polymerase functional domains of PEDV with other five porcine coronaviruses indicated a broader antiviral spectrum for the three compounds. Generally, RDV-N is a promising broad-spectrum antiviral nucleoside, and it would be worthy to make some structural modifications to increase its oral bioavailability.
Asunto(s)
Adenosina Monofosfato/análogos & derivados , Alanina/análogos & derivados , Infecciones por Coronavirus , Citidina/farmacología , Virus de la Diarrea Epidémica Porcina , Enfermedades de los Porcinos , Adenosina Monofosfato/farmacología , Alanina/farmacología , Animales , Chlorocebus aethiops , Citidina/análogos & derivados , Ratones , Nucleósidos/farmacología , Padres , Virus de la Diarrea Epidémica Porcina/efectos de los fármacos , Porcinos , Células VeroRESUMEN
Currently, remdesivir is the first and only FDA-approved antiviral drug for COVID-19 treatment. Adequate supplies of remdesivir are highly warranted to cope with this global public health crisis. Herein, we report a Weinreb amide approach for preparing the key intermediate of remdesivir in the glycosylation step where overaddition side reactions are eliminated. Starting from 2,3,5-tri-O-benzyl-d-ribonolactone, the preferred route consisting of three sequential steps (Weinreb amidation, O-TMS protection, and Grignard addition) enables a high-yield (65%) synthesis of this intermediate at a kilogram scale. In particular, the undesirable PhMgCl used in previous methods was successfully replaced by MeMgBr. This approach proved to be suitable for the scalable production of the key remdesivir intermediate.
Asunto(s)
Adenosina Monofosfato/análogos & derivados , Alanina/análogos & derivados , Amidas/química , Antivirales/síntesis química , Adenosina Monofosfato/síntesis química , Alanina/síntesis químicaRESUMEN
In the title compound, [Ag(C(7)H(7)O(3)S)(C(13)H(14)N(2))](n), the Ag(I) ion is coordinated in a T-shape by two N atoms from two symmetry-related 1,3-bis-(pyridin-4-yl)propane ligands and one O atom from a p-toluene-sulfonate ligand, forming a one-dimensional zigzag chain along [001]. In the crystal, weak C-Hâ¯O hydrogen bonds and weak Agâ¯Ag inter-actions [3.2628â (5)â Å] are observed.